RHY Stock Overview
Engages in developing and commercializing medical diagnostics technology in Australia and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rhythm Biosciences Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.068 |
52 Week High | AU$0.56 |
52 Week Low | AU$0.068 |
Beta | 2.7 |
1 Month Change | -26.88% |
3 Month Change | -30.61% |
1 Year Change | -84.89% |
3 Year Change | -94.31% |
5 Year Change | -57.50% |
Change since IPO | -79.08% |
Recent News & Updates
Recent updates
Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?
Dec 06We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate
Aug 09We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely
Apr 11Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation
Dec 02We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely
Jul 19Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation
Mar 03Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?
Dec 03Shareholder Returns
RHY | AU Healthcare | AU Market | |
---|---|---|---|
7D | -12.8% | -1.6% | 1.3% |
1Y | -84.9% | -20.7% | 8.8% |
Return vs Industry: RHY underperformed the Australian Healthcare industry which returned -20.7% over the past year.
Return vs Market: RHY underperformed the Australian Market which returned 8.8% over the past year.
Price Volatility
RHY volatility | |
---|---|
RHY Average Weekly Movement | 6.4% |
Healthcare Industry Average Movement | 6.7% |
Market Average Movement | 9.0% |
10% most volatile stocks in AU Market | 17.5% |
10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: RHY's share price has been volatile over the past 3 months.
Volatility Over Time: RHY's weekly volatility has decreased from 15% to 6% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | n/a | n/a | www.rhythmbio.com |
Rhythm Biosciences Limited, engages in developing and commercializing medical diagnostics technology in Australia and internationally. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.
Rhythm Biosciences Limited Fundamentals Summary
RHY fundamental statistics | |
---|---|
Market cap | AU$16.73m |
Earnings (TTM) | -AU$8.63m |
Revenue (TTM) | AU$2.07m |
8.1x
P/S Ratio-1.9x
P/E RatioIs RHY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RHY income statement (TTM) | |
---|---|
Revenue | AU$2.07m |
Cost of Revenue | AU$2.04m |
Gross Profit | AU$27.30k |
Other Expenses | AU$8.66m |
Earnings | -AU$8.63m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.035 |
Gross Margin | 1.32% |
Net Profit Margin | -417.89% |
Debt/Equity Ratio | 0% |
How did RHY perform over the long term?
See historical performance and comparison